METHOD OF CULTURING PROLIFERATIVE HEPATOCYTES
A method of culturing animal cells, preferably primary hepatocytes, including a first step of culturing the animal cells in non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel, a second step of embedding the animal cells in a collagen matrix or in a gelatin matrix, and a third step of culturing the animal cells embedded in the collagen matrix or in the gelatin matrix, thereby obtaining 3D animal cell structures including proliferative animal cells, preferably spheroids including proliferative primary hepatocytes. Also, a spheroid including proliferative primary hepatocytes and the uses thereof for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the liver toxicity, genotoxicity and/or the effects of a drug or a compound.
1 - 15 . (canceled)
16 . A method of culturing animal cells to obtain 3D animal cell structures comprising proliferative animal cells, said method comprising:
a) first culturing the animal cells in a non-adherent culture vessel;
b) then transferring the animal cells to a culture medium comprising collagen, or truncated collagen also known as gelatin, thereby embedding the animal cells in a collagen or gelatin matrix; and
c) culturing the animal cells embedded in the collagen or gelatin matrix;
thereby obtaining 3D animal cell structures comprising proliferative animal cells.
17 . The method according to claim 16 , said method comprising:
a) first culturing the animal cells in a non-adherent culture vessel;
b) then transferring the animal cells to a culture medium comprising collagen, thereby embedding the animal cells in a collagen matrix; and
c) culturing the animal cells embedded in the collagen matrix;
thereby obtaining 3D animal cell structures comprising proliferative animal cells.
18 . The method according to claim 17 , wherein at step b) the animal cells are transferred to a culture medium comprising collagen at a concentration ranging from about 0.25 mg/mL to about 3 mg/mL.
19 . The method according to claim 17 , wherein at step b) the animal cells are transferred to a culture medium comprising fibrillar collagen.
20 . The method according to claim 17 , wherein at step b) the animal cells are transferred to a culture medium comprising fibrillar collagen selected from the group consisting of type I collagen, type II collagen, type III collagen, type V collagen, type VI collagen, type XI collagen, type XXIV collagen, type XXVII collagen and any mixtures thereof.
21 . The method according to claim 16 , said method comprising:
a) first culturing the animal cells in a non-adherent culture vessel;
b) then transferring the animal cells to a culture medium comprising methacrylated gelatin (GelMa), thereby embedding the animal cells in a GelMa matrix; and
c) culturing the animal cells embedded in the GelMa matrix;
thereby obtaining 3D animal cell structures comprising proliferative animal cells
22 . The method according to claim 21 , wherein at step b) the animal cells are transferred to a culture medium comprising methacrylated gelatin (GelMa) at a concentration ranging from about 1% (w/v) to about 20% (w/v).
23 . The method of claim 16 , wherein at step a) the non-adherent culture vessel is a low or ultra-low attachment culture vessel.
24 . The method according to claim 16 , wherein at step a) the animal cells are cultured in a non-adherent culture vessel for a period ranging from about 1 h to about 96 h.
25 . The method according to claim 16 , further comprising a fourth step of adding an inhibitor of the MAPK MEK1/2-ERK1/2 pathway to the culture of animal cells embedded in the collagen or gelatin matrix, thereby inducing one or more additional wave(s) of proliferation of the animal cells.
26 . The method according to claim 16 , further comprising a last step of incubating the 3D animal cell structures comprising proliferative animal cells embedded in the collagen or gelatin matrix with a collagenase or an enzyme mixture with collagenolytic activity, thereby isolating the 3D animal cell structures comprising proliferative animal cells from the collagen or gelatin matrix.
27 . The method according to claim 16 , wherein the animal cells are primary hepatocytes, and the 3D animal cell structures comprising proliferative animal cells are spheroids comprising proliferative primary hepatocytes.
28 . The method according to claim 16 , wherein the animal cells are primary human hepatocytes, and the 3D animal cell structures comprising proliferative animal cells are spheroids comprising proliferative primary human hepatocytes and having an acinus-like structure with a hollow lumen.
29 . A spheroid comprising proliferative primary hepatocytes embedded in a collagen or gelatin matrix, wherein said spheroid has an acinus-like structure with a hollow lumen.
30 . The spheroid according to claim 29 , wherein said proliferative primary hepatocytes are proliferative primary human hepatocytes.
31 . An in vitro method of assessing the liver toxicity, the liver genotoxicity and/or the effects of a drug or a compound, the method comprising:
a) obtaining 3D animal cell structures comprising proliferative animal cells according to the method of claim 16 ;
b) contacting the 3D animal cell structures comprising proliferative animal cells with a drug or a compound; and
c) assessing the liver toxicity, the liver genotoxicity and/or the effects of the drug or the compound on the 3D animal cell structures comprising proliferative animal cells.
32 . The in vitro method according to claim 31 , wherein the 3D animal cell structures comprising proliferative animal cells are spheroids comprising proliferative primary hepatocytes.
33 . The in vitro method according to claim 31 , wherein the 3D animal cell structures comprising proliferative animal cells are spheroids comprising proliferative primary human hepatocytes and having an acinus-like structure with a hollow lumen.